| Website | chiasmapharma.com |
| Category | BioTech |
| Phone | 972-2-571-5885 |
| Employees |
| TOTAL | $90.2M |
| FUNDING TOTAL | $90.2M |
| Series B, 9/05 Jerusalem Global Ventures Ofer Hi-Tech Yissum Research Development F2 Ventures | $7.7M |
| Series C, 11/06 MPM Capital ARCH Venture Partners Ofer Hi-Tech F2 Ventures | $44M |
| Series D, 7/12 Abingworth MPM Capital ARCH Venture Partners | $38.5M |
| DEBT TOTAL | $22M |
| Debt, 3/11 | $9M |
| Debt, 6/11 | $10M |
| Debt, 6/12 | $3M |
Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company’s Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.